Advertisement

Topics

Companies Related to "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma" [Most Relevant Company Matches] RSS

09:33 EST 20th February 2019 | BioPortfolio

Here are the most relevant search results for "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma" found in our extensive corporate database of over 50,000 company records.

Showing "Safety Immune Tumor Response Multi component Immune Based" Companies 1–25 of 8,000+

Extremely Relevant

IRX Therapeutics, Inc.

IRX Therapeutics is a clinical-stage company developing novel immunotherapies focused on reducing the immune suppression that is seen in the cancer tumor micro-environment, restoring immune function, and activating a coordinated immune response against the tumor. The lead candidate, IRX-2, is a proprietary therapeutic containing numerous active cytokine co...


Checkmate Pharmaceuticals, Inc.

Checkmate Pharmaceuticals is a research and development company pursuing a novel approach to specifically activating the innate arm of the immune system to recognize and ultimately destroy tumor cells. The company is leveraging their expertise and the vast body of knowledge in the field of CpG oligonucleotides and is validating an approach that will combine ...

BIO-LOGIC SOLUTIONS

A start-up biomedical company with a novel approach to treating cancer. Our approach is logical. There are specific chemicals associated with tumors which block immune attack. By neutralizing these chemicals and stimulating immune response, we are able to initiate a spontaneous remission of the tumor.Our treatment concept has been accepted by the Patent Cooperation Treaty (PCT) as novel, inventi...


Advaxis

Advaxis, Inc. is a biotechnology company that uses a modified infectious microorganism to activate the immune system to treat cancer, infectious disease or allergic syndromes. Based upon over a 10 years of innovative work done by Yvonne Paterson, Ph.D., Professor of Microbiology at the University of Pennsylvania, it has been found that the unique microbe Listeria monocytogenes is capable of stimul...

Kyn Therapeutics

Kyn Therapeutics is a biotechnology company advancing new immunometabolic therapies for cancer. A growing body of research indicates that key metabolites can exert broad suppressive or enhancing effects on the immune system through a complex network of cellular interactions, providing targets for new therapies that could significantly enhance patient respo...

MabSpace Biosciences Co., Limited

MabSpace Biosciences Co., Ltd. is a private, venture-backed biotechnology company specialized in discovering and developing innovative antibody therapeutics using its proprietary immune tolerance breaking technology platform. MabSpace has built up a pipeline in immune-oncology, ophthalmology as well as nephrology. The immune-oncology (IO) pipeline is spear...

Immunitor Corporation Co., Ltd

Immunitor Corporation Co., Ltd., is the first private biotech company formed in Thailand Technology developed by Immunitor allows to formulate any desired immunogen or antigen as an oral tablet.Such antigens are formulated into an ordinary appearing pill in such a way that they can withstand the digestive degradation in the stomach but are capable to trigger immune response once pr...

Immune Design Corp.

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease. The company’s technologies are engineered to activate the immune system’s natural ability to create and/or expand antigen-specific cytotoxic T cells, while enhancing other immune effectors,...

AC Vaccine technology

The AC Vaccine technology is a therapuetic treatment based on the concept of haptenization. This idea has a long history, beginning with the work of the immunologist and Nobel laureate Karl Landsteiner in the 1920’s. He and other scientists showed in animal models that attaching a small chemical (a hapten) to a protein allowed that protein to be recognized by the immune system even if the anim...

Amazon Biotech

Amazon Biotech (OTCBB: AMZB) was established in 2003 to focus on the research and development of novel all-natural drugs for a better quality of life, by using the best of traditional medicines from the Amazon and Mother Nature. Amazon Biotech goal is to be a world leader and contributor in the treatment of HIV naturally through the use of Immune-based therapies (IBT). An Immune-Based Therapy i...

The Immune Response Corporation

The Immune Response Corporation (OTCBB: IMNR.OB) is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company’s lead immune-based therapeutic product candidates are NeuroVax™ for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimula...

Tizona Therapeutics, Inc.

Tizona Therapeutics, Inc., is a privately held immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune disorders. A healthy immune system integrates information from pro-inflammatory and anti-inflammatory cells that regulate the immune system’s function. In cancer, tumor cells evade recognition by c...

Gritstone Oncology, Inc.

Gritstone is a privately-held company developing personalized cancer immunotherapies to fight multiple cancer types. Gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors and deep financial backing to tackle fundamental challenges at the intersection of cancer g...

PIN Pharma, Inc.

PIN Pharma is a pre-IND stage venture backed immunotherapy company focused on the development of PINS (precision immune stimulants). The lead compound PIN-2 is a first-in-class, novel, next-generation engineered peptide that empowers the immune system in vivo. The Company’s technology primes the innate immune system to modulate adaptive immunity there...

Inotrem S.A.

Inotrem is a biotechnology company specialized in the control of excessive immune response that occurs in acute inflammatory syndromes in the critical care setting. It has developed a new concept of immunomodulation to control abnormal immune response to tissue injuries, using a personalized medicine approach. The Company has been founded in 2013 in Nancy ...

BryoLogyx

BryoLogyx is developing a new class of drugs to enhance the response rates and treatment durability of cancer immunotherapies and anti-HIV agents. The company’s initial focus is on cancer, where it capitalizing on two recent scientific advances: the discovery that a complex natural product, bryostatin, stimulates tumor antigen production to amplify the ...

Turnstone Biologics

Turnstone Biologics is a clinical-stage, immuno-oncology company focused on the development of next-generation oncolytic viral immunotherapies for patients with a broad range of solid tumors. Turnstone’s unique, first-in-class oncolytic viral immunotherapies combine the potent tumor-killing effects of an oncolytic virus with a tumor-targeted T-cell va...

Quentis Therapeutics Inc.

Quentis Therapeutics is a preclinical stage biotechnology company that is pursuing first-in-class endoplasmic reticulum (ER) stress response-targeted therapies to address serious diseases such as cancer. Based on our deep expertise in ER stress biology and the tumor microenvironment, we are pioneering the use of ER stress response modulators to boost the i...

FlowMetric Diagnostics Inc.

FlowMetric Diagnostics, an affiliate of FlowMetric Inc., based in Doylestown, PA and founded in December 2013, utilizes a flow cytometry-based platform to analyze cell-mediated immune responses. The company’s proprietary assays require only small volumes of capillary blood, eliminating the need for venous blood draw. The technology can be readily adap...

Tempest Therapeutics Inc.

Tempest Therapeutics is a development-stage biotechnology company advancing small molecules that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and potential best-in-class small molecule therapeutics that modulate distinct immune response pathways relevant to mounting an effective anti-tumor...

Biothera Pharmaceuticals, Inc.

Biothera is a privately held biotechnology company developing Imprime PGG, a clinical stage immunotherapy drug that modulates key immune cells to orchestrate a coordinated immune response to cancer that involves both the innate and adaptive immune system. Proof of concept has been established from single-arm and randomized phase 2 studies in non-small cell...

Immune-Onc Therapeutics, Inc.

Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a newly established biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment. The Company is applying the latest scientific insights and expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer pat...

Surface Oncology, Inc.

Surface is creating the next generation of immunotherapies for cancer. To fully unlock the potential of cancer immunotherapy, Surface is targeting a broader set of immune processes by which cancer cells evade immune recognition and attack. Our programs are built upon emerging, proprietary insights about how to improve the immune system’s recognition a...

Relevant

Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. was founded in 2015 and is focused on developing novel protein‐based immunotherapies using its proprietary variant immunoglobulin domain (vIgD) platform technology. The vIgD platform is designed to create novel therapeutics that modulate multiple therapeutic targets, including many present in the immune synapse. Alpine's v...

Pharmexa A/S

Pharmexa is a leading company in the field of therapeutic vaccines (pharmaccines) for the treatment of serious chronic diseases. Pharmexa’s proprietary AutoVac™ pharmaccine technology platform is broadly applicable, but the company currently focuses its resources on a number of cancer forms and chronic inflammatory diseases. Pharmexa´s product pipeline targets breast cancer, rheumatoid arthri...


More From BioPortfolio on "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks